Brief: Advaxis Updates Prolonged Survival Data In Phase 1/2 ADXS-PSA Trial

Ayala Pharmaceuticals

07/10/2019 13:18

Oct 7 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS ANNOUNCES UPDATED PROLONGED SURVIVAL DATA IN PHASE
1/2
ADXS-PSA TRIAL
    * ADVAXIS INC - MEDIAN OVERALL SURVIVAL FOR ADXS-PSA IN
COMBINATION WITH KEYTRUDA(®) INCREASED TO 33.6 MONTHS FROM
PREVIOUSLY REPORTED 21.1 MONTHS
    * ADVAXIS INC - COMBINATION OF ADXS-PSA AND KEYTRUDA(®) HAS
APPEARED TO BE WELL-TOLERATED

Source text for Eikon:  ID:nBw2HDM9Ra 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))